Search research articles
Contact Us
Filters
Showing results (1-10 of 39) with videos related to
Page
of 4
Sort By:
Der Nervenarzt
|
February 20, 2015
[Do new oral therapies show advantages in the basal therapy of multiple sclerosis? Pro]
S G Meuth
European Journal of Neurology
|
June 5, 2020
Stem cell transplantation and alemtuzumab - options for 'early reprogramming' in multiple sclerosis?
S Pfeuffer, S G Meuth
Clinical and Experimental Immunology
|
September 17, 2013
Disease-modifying therapy in multiple sclerosis and chronic inflammatory demyelinating polyradiculoneuropathy: common and divergent current and future strategies
N Melzer, S G Meuth
Der Nervenarzt
|
March 30, 2016
[Actual medical care situation and therapeutic needs in multiple sclerosis: Impact of the Pharmaceutical Market Restructuring Act (AMNOG)]
S Bittner, S G Meuth
Der Nervenarzt
|
August 11, 2022
[Multiple sclerosis: interventions to halt disease : Which patients can be considered for autologous stem cell transplantation]
A G Willison, S G Meuth
Der Nervenarzt
|
February 7, 2018
[Coagulation factors and multiple sclerosis : Key factors in the pathogenesis?]
K Göbel, C Kleinschnitz, S G Meuth
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
July 3, 2009
Dose-dependent melanonychia by mitoxantrone
C Reinsberger, S G Meuth, H Wiendl
Mathematical Medicine and Biology : a Journal of the IMA
|
November 1, 2015
Insights from mathematical modelling for T cell migration into the central nervous system
T Ruck, S Bittner, S G Meuth, et al.
Der Nervenarzt
|
June 25, 2013
[Alemtuzumab for relapsing-remitting multiple sclerosis. Results of two randomized controlled phase III studies]
L Klotz, S G Meuth, B Kieseier, et al.
Der Nervenarzt
|
March 11, 2018
[Cladribine tablets : Oral immunotherapy of relapsing-remitting multiple sclerosis with short yearly treatment periods]
S G Meuth, T Ruck, O Aktas, et al.
Page
of 4
Search research articles
Search
Showing results (1-10 of 39) with videos related to
Sort By:
Page
of 4
Der Nervenarzt
|
February 20, 2015
[Do new oral therapies show advantages in the basal therapy of multiple sclerosis? Pro]
S G Meuth
European Journal of Neurology
|
June 5, 2020
Stem cell transplantation and alemtuzumab - options for 'early reprogramming' in multiple sclerosis?
S Pfeuffer, S G Meuth
Clinical and Experimental Immunology
|
September 17, 2013
Disease-modifying therapy in multiple sclerosis and chronic inflammatory demyelinating polyradiculoneuropathy: common and divergent current and future strategies
N Melzer, S G Meuth
Der Nervenarzt
|
March 30, 2016
[Actual medical care situation and therapeutic needs in multiple sclerosis: Impact of the Pharmaceutical Market Restructuring Act (AMNOG)]
S Bittner, S G Meuth
Der Nervenarzt
|
August 11, 2022
[Multiple sclerosis: interventions to halt disease : Which patients can be considered for autologous stem cell transplantation]
A G Willison, S G Meuth
Der Nervenarzt
|
February 7, 2018
[Coagulation factors and multiple sclerosis : Key factors in the pathogenesis?]
K Göbel, C Kleinschnitz, S G Meuth
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
July 3, 2009
Dose-dependent melanonychia by mitoxantrone
C Reinsberger, S G Meuth, H Wiendl
Mathematical Medicine and Biology : a Journal of the IMA
|
November 1, 2015
Insights from mathematical modelling for T cell migration into the central nervous system
T Ruck, S Bittner, S G Meuth, et al.
Der Nervenarzt
|
June 25, 2013
[Alemtuzumab for relapsing-remitting multiple sclerosis. Results of two randomized controlled phase III studies]
L Klotz, S G Meuth, B Kieseier, et al.
Der Nervenarzt
|
March 11, 2018
[Cladribine tablets : Oral immunotherapy of relapsing-remitting multiple sclerosis with short yearly treatment periods]
S G Meuth, T Ruck, O Aktas, et al.
Page
of 4